Quantification of mast cells in oral reactive lesions - an immunohistochemical study Mast cells in oral reactive lesions

Main Article Content

Sita Mahalakshmi Baddireddy https://orcid.org/0000-0001-7196-1456
Satya Tejaswi Akula https://orcid.org/0000-0002-1544-4136
Jithender Nagilla
Ravikanth Manyam https://orcid.org/0000-0001-6952-5014

Keywords

Reactive lesions, mast cell, tryptase, immunohistochemical analysis.

Abstract

Background: Reactive lesions (RLs) are the most common oral mucosal lesions that are benign in nature and are more likely to reoccur if the lesion or local irritants at the site are not completely removed. The histopathology is usually determined by the stage of the lesion, which includes neovascularization, inflammation, and fibrosis etc.


Aim: To evaluate and compare mast cell counts in different reactive lesions with normal gingiva (NG) and to determine the correlation between mast cell count and inflammation, fibrosis, and angiogenesis using immunohistochemistry.


Materials & Methods:  10 pyogenic granulomas (early and late), 10 irritational fibromas, 5 inflammatory fibrous hyperplasia, and 5 peripheral cemento-ossifying fibromas 5 normal gingiva were evaluated. Mast cell counts were compared. ANOVA and t-tests were used to analyze the data. Spearman correlation was used to compare the mast cell count to the inflammation, fibrosis, and vascular components. A p-value of 0.05 was considered statistically significant.


Results: The mean number of mast cells were increased in oral reactive lesions when compared to NG. Although mast cells were significantly higher in IFH and IF, there was no correlation found among mast cells and fibrosis/inflammation/vascularity.


Conclusion: Reactive process involves multiple interactions among mast cells, endothelial cells, fibroblasts, and other immune cells, among which the role of mast cells has been evaluated. Mast cell count increases in these reactive lesions, possibly reflecting an important role in microenvironment modification, but it is not the sole cause of these lesions’ pathogenesis.

Downloads

Download data is not yet available.
Abstract 64 | PDF Downloads 52

References

1. Reddy V, Saxena S, Saxena S, Reddy M. Reactive hyperplastic lesions of the oral cavity: A ten year observational study on North Indian Population. J Clin Exp Dent. 2012;4(3):e136-40.
2. Shukla P, Dahiya V, Kataria P, Sabharwal S. Inflammatory hyperplasia: From diagnosis to treatment. J Indian Soc Periodontol. 2014;18(1):92-4.
3. Zarei MR, Chamani G, Amanpoor S. Reactive hyperplasia of the oral cavity in Kerman province, Iran: a review of 172 cases. Br J Oral Maxillofac Surg. 2007;45(4):288-92.
4. Jafarzadeh H, Sanatkhani M, Mohtasham N. Oral pyogenic granuloma: a review. J Oral Sci. 2006;48(4):167-75.
5. Farahani SS, Navabazam A, Ashkevari FS. Comparison of mast cells count in oral reactive lesions. Pathol Res Pract. 2010;206(3):151-5.
6. Shetty DC, Urs AB, Ahuja P, Sahu A, Manchanda A, Sirohi Y. Mineralized components and their interpretation in the histogenesis of peripheral ossifying irritational fibroma. Indian J Dent Res. 2011;22(1):56-61.
7. Kamal R, Dahiya P, Puri A. Oral pyogenic granuloma: Various concepts of etiopathogenesis. J Oral Maxillofac Pathol. 2012;16(1):79-82.
8. Krystel-Whittemore M, Dileepan KN, Wood JG. Mast Cell: A Multi-Functional Master Cell. Front Immunol. 2015;6:620.
9. Metcalfe DD, Boyce JA. Mast cell biology in evolution. J Allergy Clin Immunol. 2006;117(6):1227-9.
10. Santos PP, Nonaka CF, Pinto LP, de Souza LB. Immunohistochemical expression of mast cell tryptase in giant cell irritational fibroma and inflammatory fibrous hyperplasia of the oral mucosa. Arch Oral Biol. 2011;56(3):231-7.
11. Walsh LJ. Mast cells and oral inflammation. Crit Rev Oral Biol Med. 2003;14(3):188-98.
12. Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, et al. The human mast cell: functions in physiology and disease. Front Biosci. 2001;6:D1109-27.
13. Reddy V, Bhagwath SS, Reddy M. Mast cell count in oral reactive lesions: A histochemical study. Dent Res J (Isfahan). 2014;11(2):187-92.
14. Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 1997;99(6):1313-21.
15. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018;282(1):121-50.
16. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;15(6):639-56.
17. Frungieri MB, Weidinger S, Meineke V, Kohn FM, Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma : Possible relevance to human fibrotic disorders. Proc Natl Acad Sci U S A. 2002;99(23):15072-7.
18. Iddamalgoda A, Le QT, Ito K, Tanaka K, Kojima H, Kido H. Mast cell tryptase and photoaging: possible involvement in the degradation of extra cellular matrix and basement membrane proteins. Arch Dermatol Res. 2008;300 Suppl 1:S69-76.
19. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110(1):126-44.
20. Fonseca-Silva T, Santos CC, Alves LR, Dias LC, Brito M, Jr., De Paula AM, et al. Detection and quantification of mast cell, vascular endothelial growth factor, and microvessel density in human inflammatory periapical cysts and granulomas. Int Endod J. 2012;45(9):859-64.